Senores Pharmaceuticals has acquired the US FDA-approved ANDA for enalapril maleate tablets in multiple dosages from Wockhardt, expanding its presence in the hypertension treatment market.

Sun Pharmaceutical has agreed to acquire Concert Pharmaceuticals for $576 million, aiming to bring deuroxilitinib, a promising JAK 1/2 inhibitor for alopecia areata, to market. This acquisition highlights the growing interest in JAK inhibitors for autoimmune diseases, with the alopecia areata market projected to reach $2.5 billion by 2030. Concert's deuroxilitinib, currently in phase 3 trials, is set to compete with established drugs from Eli Lilly and Pfizer.

Faron Pharmaceuticals has successfully raised €12 million through an oversubscribed share placing, exceeding their initial €10 million target due to strong investor confidence.

Quoin Pharmaceuticals initiates an investigator-led clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome, a condition with no approved treatments.

Quoin Pharmaceuticals initiates a clinical study in New Zealand for QRX003 targeting Peeling Skin Syndrome, a condition with no approved treatments.

Longboard Pharmaceuticals has started a Phase 3 clinical trial, DEEp SEA, to assess bexicaserin in Dravet syndrome patients aged 2-65 years.

Kiora Pharmaceuticals reported a strong financial position with $29.0 million in cash and equivalents, extending the cash runway into 2027.

Corvus Pharmaceuticals reported a net loss of $6.7 million for Q4 2023, with R&D expenses totaling $4 million. The company is preparing for Phase 3 trials of soquelitinib for PTCL and a Phase 1 trial for atopic dermatitis in 2024, highlighting significant market opportunities and clinical progress.

Phathom Pharmaceuticals presented data on VOQUEZNA® (vonoprazan) at the ACG 2024 meeting, highlighting its efficacy in treating GERD.

OliX Pharmaceuticals has commenced a Phase I clinical trial in Australia for OLX72021, an RNAi therapeutic aimed at treating androgenic alopecia, also known as male-pattern baldness. The trial focuses on assessing the safety, tolerability, and pharmacokinetics of a single intradermal injection of OLX72021.

Foresee Pharmaceuticals' Phase 3 trial of Leuprolide (FP-001) for central precocious puberty (CPP) receives a second positive recommendation from the Data and Safety Monitoring Board (DSMB).

Madrigal Pharmaceuticals reported $62.2 million in net sales for Q3 2024, driven by the U.S. launch of Rezdiffra™ (resmetirom).

New data suggests ciforadenant, an adenosine A2A receptor antagonist, can overcome resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).

New data suggests ciforadenant, an adenosine A2A receptor antagonist, can enhance sensitivity to anti-PD1 therapy in metastatic castration-resistant prostate cancer (mCRPC).

The FDA has approved sodium oxybate (Lumryz) for treating cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients aged 7 and older.

Bambusa Therapeutics has successfully closed a Series Seed financing round, raising approximately $15 million to advance its bispecific antibody programs.

• Accord BioPharma's Hercessi (trastuzumab-strf), a biosimilar to Herceptin, has received FDA approval for its 420mg strength, expanding treatment options for HER2-overexpressing cancers. • The approval includes indications for adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. • Clinical data demonstrated Hercessi's similarity to Herceptin in efficacy, safety, and quality, supporting its use as a cost-effective alternative. • Accord BioPharma plans to commercially launch Hercessi in the U.S. in early 2025, adding to their growing portfolio of biosimilars aimed at reducing healthcare costs.

Medipost Inc. is expanding its U.S. presence with key executive appointments to drive its regenerative therapy, CARTISTEM, toward a Phase III clinical trial.

Oragenics' ONP-002, a neurosteroid delivered intranasally, is advancing to Phase II clinical trials for treating moderate to severe concussions.

Rapport Therapeutics receives a Buy rating from JonesTrading, driven by its innovative RAP platform targeting central nervous system disorders.